Now Clinically Proven!

"Our initial experience with the BCA graft began in 2004 and our early impression of this conduit was that it resulted in less inflammatory response at the site of implantation and less infectious complications while also allowing for easier surgical handling."

"Between April 4, 2006 and February 2, 2009, a total of 220 arteriovenous graft-related surgeries were performed."

"Enrollment in this study was open to all 110 patients with AVG placement that were not candidates for native AVF as permanent AV access."

"Of these patients, 57 who gave their consent to enroll in the study were prospectively randomized to receive either the Artegraft or cuffed ePTFE graft."

"Our results show that the primary and assisted patencies of BCA grafts are superior to ePTFE conduits with a consistently lower overall complications rate."

"The BCA graft survival advantage was most profound in the upper arm grafts with significantly higher primary and assisted patency rates."

"The complication rates are comparably low in the BCA grafts and fewer interventions are required to achieve these prolonged secondary patency rates."

"Conclusion: The BCA graft is an excellent option for patients on hemodialysis that are not eligible for native arteriovenous fistulas, as these grafts required fewer interventions than the ePTFE grafts to maintain patency."